Advertisement
ABT vs MDT
ABT vs MDT Stock Comparison: MDT's Earnings Surge Outpaces ABT's Acquisition-Driven Strategy
Key Takeaways
- Medtronic has delivered stronger year-to-date returns of approximately 23%, compared to Abbott Laboratories' 12%, reflecting robust demand in cardiovascular devices.
- Abbott's recent acquisition of Exact Sciences bolsters its diagnostics segment, potentially enhancing long-term growth amid challenges in nutrition and diagnostics sales.
- Medtronic's earnings beat and raised guidance highlight operational efficiency, while Abbott's missed revenue estimates signal short-term pressures.
- Both companies maintain solid dividend yields, with Medtronic at 2.95% offering higher income appeal for conservative investors.
- Market sentiment favors Medtronic's focused medical device exposure over Abbott's diversified healthcare portfolio in the current environment.
- Risk profiles differ, with Medtronic's spinoff plans introducing uncertainty, contrasted by Abbott's stable but slower-growth segments.
Introduction
Abbott Laboratories (ABT) and Medtronic (MDT) are prominent players in the medical technology and healthcare sectors, making them compelling for comparison as investors navigate evolving market conditions. Abbott's diversified operations span diagnostics, nutrition, pharmaceuticals, and devices, while Medtronic focuses primarily on innovative medical devices for chronic conditions. This analysis is particularly relevant for long-term investors seeking stability in healthcare amid economic fluctuations, or traders monitoring momentum shifts driven by regulatory approvals, earnings reports, and sector trends. By examining their relative performance, business models, and market positioning, stakeholders can better assess opportunities in a space influenced by aging populations and technological advancements.
ABT Overview and Recent Performance
Abbott Laboratories operates as a global healthcare leader with segments in diagnostics, medical devices, nutrition, and established pharmaceuticals, serving over 160 countries. Its portfolio includes continuous glucose monitors like FreeStyle Libre and cardiovascular products, driving revenue through innovation and acquisitions.
In recent weeks, ABT's stock has shown moderate gains, with year-to-date returns around 12%, underperforming broader indices amid mixed sentiment. Key influences include a major acquisition of cancer diagnostics firm Exact Sciences in November, valued at up to $23 billion, aimed at expanding oncology capabilities and offsetting weaknesses in other areas. However, third-quarter revenue missed analyst expectations due to softer diagnostics and nutrition sales, though medical devices performed strongly. A device correction for certain glucose sensors added caution, but FDA clearance for the Volt pulsed field ablation system supports positive device momentum. Overall, market positioning reflects resilience in diversified operations, with a forward P/E of about 22 and dividend yield of 2.02% appealing to income-focused holders.
MDT Overview and Recent Performance
Medtronic specializes in medical devices and therapies for cardiovascular, neurological, and other chronic conditions, with products like pacemakers, stents, and insulin pumps distributed worldwide. Its focus on minimally invasive technologies positions it as a key innovator in healthcare delivery.
Recent market activity has favored MDT, with year-to-date returns nearing 23%, outpacing peers amid positive earnings developments. In November, the company exceeded second-quarter estimates and raised its full-year sales growth forecast, driven by strong demand for heart devices, leading to a nearly 5% share increase. The filing for an IPO of its diabetes business, MiniMed, in December signals strategic restructuring to unlock value. Board enhancements following activist investor involvement have bolstered governance perceptions. With a forward P/E around 17 and a higher dividend yield of 2.95%, sentiment leans toward operational strength, though spinoff-related transitions introduce some volatility in near-term outlooks.
AI Trading Bot Perspective
Tickeron provides AI-driven trading bots tailored to specific stocks, offering automated strategies based on technical analysis. For ABT, the Trend Trader for Beginners: Strategy for Large-Cap Stocks (60min, TA) employs a trend-following approach on a 60-minute timeframe, using machine learning to identify aligned short-, medium-, and long-term trends in large-cap stocks. It limits open positions to 15, incorporates trailing stops, and sets a 2% take-profit target, with historical annualized returns of +26% over 714 days in simulated environments.
For MDT, the MDT – AI Trading Agent with corridor TP/SL, 60min utilizes a corridor-based strategy on a 60-minute timeframe, incorporating take-profit and stop-loss mechanisms to manage range-bound trades.
Head-to-Head Comparison
Abbott and Medtronic differ in business models, with Abbott's broader diversification across diagnostics and nutrition providing stability but diluting focus, while Medtronic's device-centric approach enables deeper innovation in high-growth areas like cardiovascular and neuromodulation. Growth drivers for Abbott include acquisitions expanding oncology exposure, contrasting Medtronic's organic gains from product demand and strategic spinoffs.
Recent momentum favors Medtronic, with superior returns reflecting earnings resilience amid sector tailwinds, whereas Abbott faces headwinds from revenue shortfalls. Risk factors include regulatory scrutiny for both, but Medtronic's lower beta (0.72) suggests less volatility compared to Abbott's broader market sensitivity. Sector exposure overlaps in devices, yet Abbott's nutrition segment adds defensive qualities during economic downturns. Overall, market sentiment tilts toward Medtronic for near-term catalysts, while Abbott appeals for long-term portfolio balance.
Tickeron AI Verdict
Based on trend consistency and recent catalysts, Tickeron's AI analysis leans toward favoring Medtronic over Abbott in the current environment. Medtronic's earnings outperformance and raised guidance indicate stronger operational momentum, potentially offering better relative positioning amid device sector demand. However, outcomes remain probabilistic, influenced by market shifts and execution risks.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and MDT is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- MDT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 5 TA indicator(s) are bullish while MDT’s TA Score has 4 bullish TA indicator(s).
- ABT’s TA Score: 5 bullish, 3 bearish.
- MDT’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -3.17% price change this week, while MDT (@Medical/Nursing Services) price change was -1.80% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.39%. For the same industry, the average monthly price growth was +1.95%, and the average quarterly price growth was -16.80%.
Reported Earning Dates
ABT is expected to report earnings on Jul 16, 2026.
MDT is expected to report earnings on Aug 25, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.39% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ABT | MDT | ABT / MDT | |
| Capitalization | 154B | 103B | 150% |
| EBITDA | 11.8B | 9.36B | 126% |
| Gain YTD | -28.819 | -15.829 | 182% |
| P/E Ratio | 24.70 | 21.50 | 115% |
| Revenue | 45.1B | 35.5B | 127% |
| Total Cash | 7.3B | 8.38B | 87% |
| Total Debt | 34B | 28.1B | 121% |
ABT | MDT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 64 | 75 | |
PRICE GROWTH RATING 1..100 | 63 | 59 | |
P/E GROWTH RATING 1..100 | 23 | 66 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABT's Valuation (3) in the Medical Specialties industry is in the same range as MDT (3). This means that ABT’s stock grew similarly to MDT’s over the last 12 months.
ABT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MDT (100). This means that ABT’s stock grew similarly to MDT’s over the last 12 months.
ABT's SMR Rating (64) in the Medical Specialties industry is in the same range as MDT (75). This means that ABT’s stock grew similarly to MDT’s over the last 12 months.
MDT's Price Growth Rating (59) in the Medical Specialties industry is in the same range as ABT (63). This means that MDT’s stock grew similarly to ABT’s over the last 12 months.
ABT's P/E Growth Rating (23) in the Medical Specialties industry is somewhat better than the same rating for MDT (66). This means that ABT’s stock grew somewhat faster than MDT’s over the last 12 months.
| ABT | MDT | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 49% | 4 days ago 70% |
| Stochastic ODDS (%) | 4 days ago 54% | 4 days ago 50% |
| Momentum ODDS (%) | 4 days ago 50% | 4 days ago 59% |
| MACD ODDS (%) | 4 days ago 57% | 4 days ago 56% |
| TrendWeek ODDS (%) | 4 days ago 54% | 4 days ago 56% |
| TrendMonth ODDS (%) | 4 days ago 49% | 4 days ago 45% |
| Advances ODDS (%) | 11 days ago 53% | 12 days ago 51% |
| Declines ODDS (%) | 20 days ago 53% | 8 days ago 58% |
| BollingerBands ODDS (%) | 4 days ago 53% | 4 days ago 50% |
| Aroon ODDS (%) | 4 days ago 48% | 4 days ago 52% |
Advertisement
ABT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with SYK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then SYK could also see price increases.
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.